All Updates

All Updates

icon
Filter
Partnerships
Exscientia partners with Charité to develop precision medicine platform
Precision Medicine
Mar 7, 2023
This week:
Product updates
Meta introduces Meta Credits digital currency for Horizon Worlds
Metaverse Platforms
Today
Product updates
Liquid AI launches STAR framework for AI model architecture optimization
Foundation Models
Today
Funding
9fin raises USD 50 million in Series B funding to expand US operations
Capital Markets Tech
Yesterday
Partnerships
Shastic partners with MeridianLink to provide AI workflow automation for financial institutions
Workflow Automation Platforms
Yesterday
Funding
KisoJi Biotechnology raises CAD 41 million to develop oncology candidate
AI Drug Discovery
Yesterday
M&A
Deel acquires UK money transfer startup Atlantic Money for undisclosed sum
Remote Work Infrastructure
Yesterday
Funding
Acorai raises EUR 4.2 million in funding to advance clinical studies
Next-gen Medical Devices
Yesterday
Product updates
Bosch announces Light Drive, an AR solution for all-day smart glasses
Extended Reality
Yesterday
Partnerships
Product updates
Vuzix expands OSHA collaboration; launches upgraded M400 AR smart glasses
Extended Reality
Yesterday
Product updates
StrikerVR launches pre-orders for consumer-facing Mavrik haptic VR gun
Extended Reality
Yesterday
Precision Medicine

Precision Medicine

Mar 7, 2023

Exscientia partners with Charité to develop precision medicine platform

Partnerships

  • UK-based AI biotechnology company Exscientia partnered with one of Europe’s largest university hospitals, Charité, to use Exscientia’s AI-based precision medicine platform in the treatment of hematological cancers.  

  • Charité will assess Exscientia’s precision medicine platform capabilities in identifying effective treatments for hematological cancer patients. This involves testing various drugs, including those that have not yet been approved for this condition, on patient samples to determine their response.  

  • The partnership will build on the findings of the EXALT-1 study. This study showed that Exscientia’s drug testing platform, which provides personalized treatment recommendations, resulted in significantly better outcomes for patients with advanced hematologic cancer compared to the treatment chosen by physicians. Charité will also create a biobank of cryopreserved blood, bone marrow, and lymph node tissues (which includes live human tissue samples) to assist in the advancement of technology and preclinical research projects at both companies.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.